Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
Phase 2
- Conditions
- Atrial FibrillationAtrial FlutterVenous Thromboembolic DiseaseMyocardial InfarctionCardiomyopathy
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- ARYx Therapeutics
- Target Recruit Count
- 600
- Registration Number
- NCT00691470
- Locations
- ๐บ๐ธ
Cardiovascular Research Institute, LLC, Canton, Ohio, United States
๐บ๐ธHeart and Vascular Clinic, Lacombe, Louisiana, United States
๐บ๐ธAndroscoggin Cardiology Associates, Auburn, Maine, United States
Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2007-11-08
- Lead Sponsor
- ARYx Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT00431782
- Locations
- ๐บ๐ธ
ARYx Investigational Site, San Antonio, Texas, United States
Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- ARYx Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT00389792
- Locations
- ๐จ๐ฆ
ARYx Investigational Sites, Montreal, Quebec, Canada
๐จ๐ฆARYx Investigational Site, Terrebonne, Quebec, Canada
ยฉ Copyright 2025. All Rights Reserved by MedPath